Medication info
Pregalin Capsule 75 mg (Pregabalin)

Pregalin Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Kips Biopharma Co., Ltd.
Appearance
Hard capsule with a reddish-brown upper part and a white lower part containing a white or light yellow powder
Packaging
100 capsules/bottle, 30 capsules/bottle
Approval status
Active

MFDS item code 202001235 · Approved 2020.02.21 · Insurance code 629701960,693202640

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see Section 5, “Patients with Renal Impairment”). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered (see Section 4, “Discontinuation of Administration”). 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ∼ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Administration Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. * : For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50 % within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose adjustment based on renal function Creatinine clearance (CLcr), (mL/min) ≥ 60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥ 30 -< 60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥ 15 -< 30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) < 15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a : The total daily dose (mg/day) should be divided as specified under the method of administration. b : The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Administration is not recommended in children under 12 years of age or adolescents aged 12 ∼ 17 years because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Kips Biopharma Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures with or without secondary generalized symptoms
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive therapy for patients with epilepsy who have partial seizures, applicable in cases with or without secondary generalized symptoms. Additionally, it helps alleviate the symptoms of fibromyalgia. It is effectively used for various neurological conditions and pain states.

How to take

Adult dose

This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see Section 5, “Patients with Renal Impairment”). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered (see Section 4, “Discontinuation of Administration”). 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ∼ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Administration Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. * : For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50 % within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose adjustment based on renal function Creatinine clearance (CLcr), (mL/min) ≥ 60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥ 30 -< 60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥ 15 -< 30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) < 15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a : The total daily dose (mg/day) should be divided as specified under the method of administration. b : The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Administration is not recommended in children under 12 years of age or adolescents aged 12 ∼ 17 years because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so if you experience mood changes or unusual behavior during treatment, you must inform your healthcare provider immediately. Patients who are allergic to any components of this drug or have a hereditary lactose intolerance should not take this medication. Diabetic patients should be cautious as weight gain may require adjustments to blood sugar control medications. If symptoms of angioedema occur, the medication should be discontinued immediately. Elderly patients may experience dizziness or drowsiness, increasing the risk of falls, and should be cautious until they become accustomed to the effects of this drug. Temporary blurred vision or changes in vision may occur, which can improve upon discontinuation of the medication. Abruptly stopping this medication may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it should be discontinued gradually under a doctor's guidance. Patients with a history of substance abuse may be at a higher risk for misuse of this medication and require special caution. Dose adjustments may be necessary for patients with impaired kidney function. Patients with heart disease should be cautious while taking this medication as symptoms of heart failure may occur. When taken with opioid analgesics, the risk of central nervous system depression is increased, so consult with a healthcare provider. This medication may cause dizziness and drowsiness, so caution is advised when driving or operating machinery. In early pregnancy, there is a risk of fetal malformation, so pregnant women should not take this medication, and women of childbearing age should use effective contraception. During breastfeeding, this drug can be transmitted to breast milk and may affect infants, so one should either stop breastfeeding or consult a doctor. In cases of overdose, symptoms such as confusion, drowsiness, and seizures may appear, and treatments such as hemodialysis may be required. Keep this medication out of reach of children, and do not transfer it into other containers. If a skin rash or a severe allergic reaction occurs while taking this medication, discontinue use immediately and inform your healthcare provider.

Side effects

  • suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal mood and behavior changes
  • angioedema
  • facial swelling
  • periorbital edema
  • upper respiratory tract edema
  • dizziness
  • drowsiness
Show 195 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • directional disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual arousal disorder
  • agitation
  • mood swings
  • emotional blunting
  • emotional elevation
  • hallucination
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • apathy
  • ataxia
  • motor coordination abnormality
  • balance disorder
  • amnesia
  • attention disorder
  • memory disorder
  • tremor
  • dysarthria
  • sensory disturbances
  • sensory reduction
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorder
  • myoclonus
  • reflex reduction
  • movement disorder
  • psychomotor agitation
  • positional vertigo
  • hypersensitivity
  • burning sensation
  • action tremor
  • syncope
  • stupor
  • muscle weakness syndrome
  • olfactory disturbances
  • loss of taste
  • writing disorder
  • diplopia
  • vertigo
  • hyperacusis
  • first-degree heart block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • breathlessness
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory reduction
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorder
  • urinary incontinence
  • reduced urine output
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falling
  • feeling intoxicated
  • altered sensation
  • fatigue
  • chest tightness
  • full-body edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reaction
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • fatigue
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • state of confusion
  • depression
  • agitation
  • restlessness
  • worsening of convulsions
  • gastrointestinal disturbances
  • tinnitus
  • sleep disorders
  • skin diseases
  • increased BUN
  • bloody stools
  • fatigue
  • weakness
  • gait abnormalities
  • decreased libido
  • sleep disorders
  • insomnia
  • ataxia
  • speech disorder
  • sensory disturbances
  • memory disorder
  • attention disorder

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture, and keep it at room temperature between 15 to 30 degrees Celsius. Storing it this way will help maintain the drug's effectiveness for a longer period.

Appearance and packaging

Appearance

Hard capsule with a reddish-brown upper part and a white lower part containing a white or light yellow powder

Package unit

100 capsules/bottle, 30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.